The Female Health Company Announces Pending Retirement of CFO Donna Felch

  The Female Health Company Announces Pending Retirement of CFO Donna Felch

Michele Greco to Assume CFO Position on January 1, 2013

PR Newswire

CHICAGO, Nov. 9, 2012

CHICAGO, Nov. 9, 2012 /PRNewswire/ -- The Female Health Company (NASDAQ-CM:
FHCO), which manufactures and markets the FC2 Female Condom^® (FC2), today
announced that Donna Felch will retire from her position as Vice President and
Chief Financial Officer effective December 31, 2012.The Company also
announced that Ms. Felch was appointed to the Company's Board of Directors on
November 7, 2012. Following her retirement, she will continue her affiliation
with the Company as a Consultant.


In connection with Ms. Felch's retirement, the Company announced that Michele
Greco will become Vice President and Chief Financial Officer effective
January1, 2013. Ms.Greco's employment with the Company commenced on
November9, 2012

O.B. Parrish, the Company's Chairman and Chief Executive Officer, noted, "I
have enjoyed working with Donna tremendously during her six year tenure as a
key member of our executive management team. On behalf of management and the
Board of Directors, I would like to express our sincere appreciation for her
contributions to The Female Health Company's success, and we are particularly
pleased that she will continue her affiliation with the Company as a
Consultant and Director."

"We are delighted to welcome Michele Greco as our new Vice President and Chief
Financial Officer," continued Parrish. "Her career with one of the world's
largest public accounting firms, where she successfully executed many
international assignments, is ideally suited to The Female Health Company's
global growth initiatives. I look forward to working with her, and we expect
a smooth transition in this key management position over the next several

Ms. Greco is a DePaul University graduate and a CPA. She has nearly 30 years
of experience in public accounting with Ernst & Young LLP, where she was named
partner in 1994 -- a position she held until March 2009. In addition to her
responsibilities as audit partner, Ms. Greco advised on a broad range of
financial transactions during her tenure at Ernst & Young, including IPO's,
mergers and acquisitions, and debt and equity transactions. She counseled
large and small clients in a variety of industries in the U.S., the U.K.,
Germany, Japan, France and the Netherlands. From January 2011 to February
2012, Ms. Greco provided consulting services to Systems Research Incorporated
as a recruiter of finance professionals. From March2009 to January2011, she
was involved in a series of personal business ventures.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and
markets the FC2 Female Condom® (FC2), which is available in the U.S. and
approximately 138 other countries globally. The Company owns certain
worldwide rights to the FC2 Female Condom®, including patents that have been
issued in the U.S., the European Union, Canada, Australia, South Africa,
Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and the
African Regional Intellectual Property Organization (ARIPO), which includes
Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia,
Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania,
Zambia and Zimbabwe. FC2 patent applications are pending in various
countries. The FC2 Female Condom® is the only available FDA-approved product
controlled by a woman that offers dual protection against sexually transmitted
diseases, including HIV/AIDS, and unintended pregnancy. The World Health
Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of

The statements in this release which are not historical facts are
forward-looking statements based upon the Company's current plans and
strategies, and reflect the Company's current assessment of the risks and
uncertainties related to its business, including such things as product demand
and market acceptance; the economic and business environment and the impact of
government pressures; currency risks; capacity; efficiency and supply
constraints; and other risks detailed in the Company's press releases,
shareholder communications and Securities and Exchange Commission filings.
Actual events affecting the Company and the impact of such events on the
Company's operations may vary from this currently anticipated.

For more information about the Female Health Company visit the Company's
website at and . If
you would like to be added to the Company's e-mail alert list, please send an
e-mail to .

SOURCE The Female Health Company

Contact: William R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch,
Press spacebar to pause and continue. Press esc to stop.